Join

or

Existing user? Login

PJ Online | PJ Letters | Herbal medicines

Home > PJ (current issue) > Letters | Search

PJ Online homeThe Pharmaceutical Journal
Vol 274 No 7346 p489
23 April 2005

This article
Reprint   Photocopy

PDF 100K, Acrobat Reader

Letters

· Council election (10)
· Statutory Committee (2)
· Herbal medicines
· Technicians (2)
· Obesity
· GlaxoSmithKline
· CPD (2)
· The profession
· Registration fees (2)


Letters to the Editor

Herbal medicines

Pharmacists’ ethical dilemma will soon be solved

From Mr T. B. Chapman, MRPharmS, and Mr C. Newbould

Alison Blenkinsopp’s article (PJ, 12 March, p296) warning of the ethical dilemma of recommending the use of St John’s wort also applies to many herbal medicines currently available.

Because of a historical loophole in the law it is possible to have unlicensed herbal medicines on display in the pharmacy alongside licensed ones.

Although there is no problem in recommending the licensed ones for their stated indications there could be problems with unlicensed ones because there is no requirement to manufacture them to good manufacturing practice (GMP) standards or to test the product for identification, assay, stability or contamination.

In addition it is prohibited to state any indications on the label of an unlicensed medicine or to use a data sheet so the pharmacist has no way of determining the product’s use in pregnancy, lactation, children or the elderly, or indeed its side effects or its drug-herb reactions. Nor is there a mechanism for the pharmacist to report any adverse events caused by the product to the authorities.

In the interest of public safety this is about to change when the UK implements the Traditional Herbal Medicinal Products Directive (THMPD) 2004/24/EC. From October 2005 all herbal medicines must have a product licence, which implies they must be manufactured to GMP by a manufacturer who holds a manufacturer’s licence.

The registration requirements will not be as onerous as a new chemical entity because as some evidence of safety and efficacy will be available based on traditional use in the EU. Additionally labels will state the medical indications, and information leaflets should provide valuable information such as dosages, contraindications and use with other medicines. It will be mandatory to report adverse reactions and to introduce a system of pharmacovigilance.

Products which were on the market before April 2004 will qualify for transitional protection under THMPD until April 2011 to enable manufacturers to comply with the regulations but if the product is not licensed by that date it will be removed from the market.

Professor Blenkinsopp’s ethical dilemma with St John’s wort could be resolved if the Medicines and Healthcare products Regulatory Agency decides to allow registration of St John’s wort but there is a possibility that this may not happen for other reasons, such as the fact that depression is not a self-diagnosable indication therefore this product would not fall within the scope of THMPD. The standardised extract also has some problems because it contains both hypericin and hyperforin and there is still debate about which one is the main active constituent.

Consequently other herbs currently in use may also fail to be registrable under the THMPD route because traditional medicines are intended to be used for ailments which the patient can self-diagnose.

If herbal medicines fail to be licensed by the THMPD route then they must be withdrawn from the market or use the normal drug route to obtain registration. The latter is expensive and protracted and may not be chosen by most of the “herbal” pharmaceutical companies because the individual market size would not support this expenditure, and consumer choice would be lost.

Tom Chapman
Chairman and EU Qualified Person

Colin Newbould
Chief Analyst and Laboratory Manager
Essential Nutrition Ltd

Send your letter to The Editor

Previous Topic (Statutory Committee)
Next Topic (Technicians)

Back to Top


©Electronicjuice

Citation: Electronicjuice URI: 20014507

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50
  • BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50
  • Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00
  • Strategic Medicines Management

    A practical guide to influencing the availability of medicines, and policies of their use. Focuses on the strategic elements of medicines management.

    £33.00
  • Introduction to Clinical Pharmaceutics (An)

    This unique textbook covers the role of basic pharmaceutics in clinical outcomes and in explaining the behaviour of medicines in the body.

    £27.00

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Rate
  • Save

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.

www.surrogacycmc.com

sellmax.com.ua